A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR, and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jul 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Everolimus (Primary) ; Vandetanib (Primary)
Indications Cancer; Non-small cell lung cancer; Solid tumours
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use

13 Jul 2023 Status changed from recruiting to active, no longer recruiting.
07 Jun 2019 Planned End Date changed from 1 May 2026 to 31 May 2026.
07 Jun 2019 Planned primary completion date changed from 1 May 2026 to 31 May 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com